DLL3 Archives

Tag: DLL3

DLL3, or Delta-like ligand 3, is a protein that plays a role in the Notch signalling pathway, which is involved in cell development and differentiation. It is particularly known for its high expression in small cell lung cancer (SCLC) and other neuroendocrine tumours, making it a potential therapeutic target. DLL3 is an inhibitory Notch ligand, meaning it can block the signalling pathway.

16 Nov 2025

By Ronny Allan

0 Comments

MP0712 (212Pb x DLL3), Radio-DARPin – DLL3 Radioligand Therapy Trial for Neuroendocrine Neoplasms

Clinical Trials and ResearchDLL3, extra, High grade neuroendocrine neoplasm (NEN), Neuroendocrine carcinoma (NEC), Peptide receptor radionuclide therapy (PRRT), PET Scan, Radioligand, Radioligand therapy, Radionuclide, Small cell lung cancer (SCLC)

Update 2nd July 2026. First patients dosed. Molecular Partners and Orano Med have dosed the first patients in a US Phase 1/2a trial of MP0712, a novel Radio-DARPin drug targeting DLL3, a protein highly expressed in small cell lung cancer and other neuroendocrine tumors. This therapy uses lead-212 to deliver targeted alpha radiation to tumors, aiming to improve treatment precision and reduce side effects. Initial safety and efficacy data are expected later in 2026, with comprehensive results anticipated in 2027. The trial is ongoing at five US sites, with more centers planned to open this year. What is Radioligand Therapy?…

25 Sep 2025

By Ronny Allan

8 Comments

Immunotherapy and Neuroendocrine Neoplasms

Clinical Trials and Research, TreatmentAdvanced neuroendocrine cancer, Anti-angiogenic therapy, Atezolizumab (Tecentriq), Avelumab (Bavencio), Avistan, Bavencio, Bevacizumab, Cisplatin, Colorectal cancer, DLL3, EGFR, Epidermal growth factor receptor (EGFR), Fluoropyrimidine, Head and Neck Cancer, Hodgkin lymphoma, Immunotherapy, Ipilimumab (Yervoy), Keytruda, Lanreotide, Melanoma, Microsatellite instability-high (MSI-H), Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Nivolumab (Opdivo), Non-small cell lung cancer (NSCLC), Paraganglioma, PD-1/PD-L1 Inhibitors, PDR001, Pembrolizumab (Keytruda), Pemetrexed disodium, Pheochromocytoma, Solid tumour, Squamous cell carcinoma, Tecentriq (Atezolizumab), Tumour mutational burden (TMB), Typical lung NET, Yervoy

Updated 24th September 2025. Introduction There's a lot of Immunotherapy stuff out there! The picture regarding its use in Neuroendocrine Neoplasms is not clear and there is no general roadmap printed. I first heard of Immunotherapy for NETs following attendance at ENETS 2017 in Barcelona. The presentation that sticks out was one given by Dr Matthew Kulke, a well-known NET Specialist in Boston. My reaction to the presentation was one of 'expectation management' and caution i.e. it's too soon to know if we will get any success and when we will get it. He also hinted that it's more likely…

01 Jul 2025

By Ronny Allan

0 Comments

Ronny Allan – a review of my blog activity Jun 2025

Awareness, Newsletters, Patient AdvocacyAdvanced neuroendocrine cancer, Bile acid malabsorption, DLL3

Here is the monthly summary of June 2025 on RonnyAllan.NET Every share helps someone understand or even work towards a diagnosis, discovery of the best doctors and treatments. The selection of top posts this month really shows the breadth of subjects applicable to Neuroendocrine Cancer that need to be considered. Click on the each of the 10 posts to read. You can share the whole post or you can share those individual posts - each has a share button or you can copy and paste the internet link (url). Use your own words, invite them to subscribe to my website and follow…

27 Jun 2025

By Ronny Allan

0 Comments

DLL3 Expression in Neuroendocrine Neoplasms – an overview

Clinical Trials and Research, TreatmentDLL3, High grade neuroendocrine neoplasm (NEN), Large cell neuroendocrine carcinoma (LCNEC), Lung NETs, Neuroendocrine carcinoma (NEC), Poorly differentiated, Small cell lung cancer (SCLC)

Updated 20th August 2025 Background - Conventional therapeutic targets for neuroendocrine tumours (NETs) include somatostatin receptors (SSTRs), mammalian Target of Rapamycin (mTOR), Vascular Endothelial Growth Factor (VEGF), and tyrosine kinases. These pathways are crucial for tumour growth, survival, and angiogenesis. The most well known is SSTRs given that most NETs express these and allows targeted therapies such as somatostatin analogues (SSA) and peptide receptor radionuclide therapy (PRRT) to be used. Other targeted therapies like everolimus and sunitinib, which inhibit mTOR and tyrosine kinases respectively. Sunitinib also targets VEGF as does cabozantinib. For neuroendocrine carcinomas (Grade 3 poorly differentiated), targeting has…